4174.TWO

OBI Pharma, Inc. [4174.TWO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

4174.TWO Stock Summary

Top 10 Correlated ETFs

4174.TWO

Top 10 Correlated Stocks

4174.TWO

In the News

4174.TWO Financial details

Company Rating
-
Market Cap
14.33B
Income
-1.15B
Revenue
41.55M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
260
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-12.34
Forward P/E
-
PEG
2.97
P/S
647.87
P/B
3.54
P/C
-
P/FCF
-8.25
Quick Ratio
26.22
Current Ratio
28.39
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5
EPS next Y
-
EPS next Q
-
EPS this Y
-35.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.74%
Revenue last 5Y
116.58%
Revenue Q/Q
60.5%
EPS Q/Q
-0.4%
-
-
-
-
SMA20
-31.93%
SMA50
-30.54%
SMA100
-33.91%
Inst Own
-
Inst Trans
-
ROA
-20%
ROE
-27%
ROC
-0.23%
Gross Margin
-285%
Oper. Margin
-5841%
Profit Margin
-5244%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
59.4-99.3
52W High
-60.15%
52W Low
-33.14%
RSI
31.04
Rel Volume
5.11
Avg Volume
448.55K
Volume
2.29M
Perf Week
-13.11%
Perf Month
-34.25%
Perf Quarter
-40.05%
Perf Half Y
-39.49%
-
-
-
-
Beta
0.982
-
-
Volatility
3.03%, 8.54%
Prev Close
0.13%
Price
39.45
Change
-3.19%

Something similar

Top by Market Cap
LLY.SW
NVDA
VOO
LLY
AVGO
Top Correlated ETFs
ZPDH.DE
XSHC.L
QDVG.DE
IHCU.L
XLVP.L
Top Correlated Stocks
DNM.L
UNP.DE
0KX9.L
3092.TW
CRLA.PA
Similar Market Cap
CNHI
000928.SZ
600675.SS
0QZF.L
603707.SS

Company Profile

Healthcare Biotechnology
  • Volume Average 448.55K
  • Market Capitalization 14.33B
  • Employee 260
  • CEO Dr. Heidi Wang Ph.D.
  • Headquarters Taipei,TW
  • IPO Date 2012-12-12
  • Website https://www.obipharma.com

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.